Allogeneic double-negative T cell therapy for relapsed acute myeloid leukemia patients post allogeneic hematopoietic stem cell transplantation: A first-in-human phase I study

Affiliations

• ¹ Department of Hematology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
• ² Blood and Cell Therapy Institute, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
• ³ Anhui Provincial Key Laboratory of Blood Research and Applications, Hefei, China.
• ⁴ Transplantation Department, Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada.
• ⁵ Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.
• ⁶ Department of Immunology, University of Toronto, Toronto, Ontario, Canada.
• ⁷ Department of Hematology, Huaibei People's Hospital, Huaibei, China.
• ⁸ R&D Center, WYZE Biotech Co., Ltd, Hangzhou, China.
• ⁹ Cell Manufacturing Department, Ruichuang Biotechnology Co., Ltd, Shaoxing, China.
• ¹⁰ Department of Hematology, Lu'an Hospital Affiliated to Anhui Medical University, Lu'an, China.
• ¹¹ Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.